Over the past decades, the treatment of multiple sclerosis (MS) has been enriched by the development of several disease modifying therapies (DMTs) with different levels of efficacy and safety (in general, inversely correlated) that can be combined in induction or escalating approaches. 1 This scenario offers the possibility of highly individualized disease management, while the tolerance toward indicators of persistent disease activity has progressively reduced. Indeed, the target of no evidence of disease activity while on treatment is gaining increasing attention. 2 With the availability of different therapeutic options, the decision on DMT change has become challenging and switching criteria are receiving continuous updates. While the presence of relapses, disability progression, and new lesions on magnetic resonance imaging (MRI) are widely acknowledged as reliable indicators of treatment failure, there is no definite consensus on the introduction of other MRI and clinical parameters, such as brain atrophy measures and cognitive decline.
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Cognitive impairment affects up to 70% of patients with MS and is detectable at every stage of the disease, from the "preclinical" stages of the radiologically isolated syndrome, the earliest phases of clinically isolated syndromes (CISs) and relapsing remitting course, to the more advanced progressive forms. 3 MS-related neuropsychological dysfunction impairs many aspects of everyday life, such as participation in social activities, driving abilities, and employment status. 4 Moreover, the presence of cognitive impairment is associated with a higher risk of both conversion from CIS to clinically definite MS 5 and disability progression over time. 6 AS for MRI correlates, cognitive deficits have been linked to greater lesion load, lesion location, gray matter lesions and atrophy, as well as discrepant patterns of cerebral activation with functional MRI. 3, 4 With this background, cognitive decline appears to be an ideal candidate in order to measure treatment response. There are, however, some issues that limit the implementation of cognitive evaluation in the therapeutic decision-making process.
The first limitation relies on the choice of measurement tools. On the basis of the neuropsychological profile of cognitive impairment in MS, several batteries have been proposed. Recently, the Brief International Cognitive Assessment for MS, a brief cognitive evaluation instrument for MS, has been developed and validated, providing solutions for the need of worldwide distribution, assessment standardization, and reliability. 7 However, the battery includes only screening measures of information processing speed, verbal and visuospatial learning, the cognitive domains more frequently involved in MS. A more comprehensive cognitive evaluation would require the use of more extensive batteries such as Rao's Brief Repeatable Battery or the Minimal Assessment of Cognitive Function in MS, which are time-consuming and lack wide international translations and validations. 3 Measurement should also take into account potential confounders such as fatigue, depression, anxiety, sleep disorders, and concomitant medications. There are no indications on how to measure and manage these confounders at the individual level. Moreover, there is no consensus on the timing of such an assessment. Of course, a baseline evaluation is needed in order to obtain a starting point. Ideally, cognitive assessment should be performed at each clinical evaluation and in the case of cognitive problems reported by the patients. With repeated assessment, however, there are limitations related to test-retest reliability and practice effects, which are only partially addressed by the use of alternative versions.
Another important issue is the definition of meaningful change, which is the definition of what "cognitive decline" actually is. Beyond the variations related to measurement issues discussed above, the evolution of neuropsychological performance in MS patients is characterized by great intra-and interindividual heterogeneity that renders it difficult to obtain at the individual level reliable cutoffs of decline for each neuropsychological measure. Even more limited is the information on ecological validity of available cognitive batteries. Patient complaints and cognitive test performances are often discrepant; for instance, monotasking assessment, performed under ideal conditions, may not capture patient-reported real-world deficits. 4 In studies attempting to provide estimates of meaningful change, test score changes have been related to objective anchors, such as vocational status or other discernible clinical variations. Efforts have been mainly devoted to the Symbol Digit Modalities Test (SDMT), which is widely acknowledged as the best measure for screening and monitoring of processing speed in MS patients. 8 Correlating SDMT with employment problems and mental status changes during relapses, a 4-point or 10% change in raw score is considered clinically relevant. Unfortunately, similar cutoffs are not available for other neuropsychological measures. Moreover, it is not clear whether the SDMT decline is the main contributor of employment restrictions or it is associated with changes in other clinical variables such as relapses, physical disability, and psychological issues. Furthermore, SDMT changes observed during relapse are, at least in part, reversible: in these cases, change meaningfulness should take into account the need for longitudinal confirmation, as it occurs for physical disability. In this regard, definition of reassessment timing is lacking (days, weeks, months?).
With these considerations in mind, the strength of cognitive change in the therapeutic decision-making process appears significantly reduced. For instance, is an isolated 4-point decline on the SDMT, with neither subjective complaints nor other clinical or MRI evidence of disease activity, enough to decide the switch from a first-line to a potentially harmful second-line treatment? Serial cognitive evaluations might provide a significant advancement in the case of isolated cognitive relapse. 9 However, the definition of isolated cognitive relapses is still under debate and currently requires the presence of neuropsychological decline and enhancing lesions at brain MRI that could constitute, per se, an indicator of disease activity or poor treatment response. Likewise, when cognitive decline occurs as part of the clinical manifestation of a relapse, its measurement would play a secondary role in establishing treatment efficacy.
In conclusion, while cognitive deficits are widely acknowledged as a core feature of MS, their utility in the therapeutic decision-making process is mainly limited by some measurement issues. In particular, the absence of the definition of a meaningful change (that has been preliminary validated only for the SDMT) hinders the interpretation of cognitive evolution over time Moreover, in the assessment of treatment efficacy, cognitive decline and physical disability progression should be considered as clinical endpoints rather than markers of treatment response. DMT switching is needed in case of ongoing disease activity, measured either by clinical relapses or MRI activity, in order to prevent physical or cognitive worsening over time. 10 When physical and cognitive disability progressions have occurred, DMT switching could be late.
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